 Humanigen Inc NASDAQ: HGEN has been informed of preliminary topline results from the ACTIV-5BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial did not achieve statistical significance on the primary. 